{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:12:18Z","timestamp":1772169138898,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/wellcomeopenres.21450.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000}}],"reference-count":28,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TRIA2015-1092"],"award-info":[{"award-number":["TRIA2015-1092"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome","doi-asserted-by":"publisher","award":["203135"],"award-info":[{"award-number":["203135"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome","doi-asserted-by":"publisher","award":["098316"],"award-info":[{"award-number":["098316"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome","doi-asserted-by":"publisher","award":["214321"],"award-info":[{"award-number":["214321"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS086312"],"award-info":[{"award-number":["R01NS086312"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["RP-2017-08-ST2-012"],"award-info":[{"award-number":["RP-2017-08-ST2-012"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joint Global Health Trials scheme","award":["MR\/P006922\/1"],"award-info":[{"award-number":["MR\/P006922\/1"]}]},{"name":"South African Research Chairs Initiative of the Department of Science and Technology and the National Research Foundation of South Africa","award":["64787"],"award-info":[{"award-number":["64787"]}]}],"content-domain":{"domain":["wellcomeopenresearch.org"],"crossmark-restriction":false},"short-container-title":["Wellcome Open Res"],"abstract":"<ns3:p>Background In Uganda where the burden of HIV-associated cryptococcal meningitis is high, conventional amphotericin B deoxycholate has been standard to manage patients with cryptococcal meningitis in research settings. However, liposomal amphotericin B (AmBisome) is now available via the efforts of UNITAID. We sought to describe our nursing experience using AmBisome within a clinical trial for cryptococcal meningitis. Methods We describe the experience of using single-dose 10mg\/kg liposomal amphotericin B from the perspective of a research nurse in Uganda. Second, we described the process of preparing and administering amphotericin. Third, we assessed the nursing time required for the administration of daily amphotericin B versus single-dose liposomal amphotericin. Fourth, we discuss the major challenges faced while using liposomal amphotericin B. Results We provide estimates for the nursing time required for reconstituting, filtering, diluting and administering liposomal amphotericin B and a visual aid for nursing tasks. Based on five trained nurses, the process of reconstitution and filtration lasts an average of 52 minutes (Range: 40 to 60 minutes), to reconstitute a mean of 11 (range: 8 to 15) 50mg vials (median weight 55kg). Overall, less nursing time was required for single-dose administration than for daily amphotericin B dosing. From a nursing perspective, liposomal amphotericin B was preferable to amphotericin B deoxycholate due to its reduced infusion reactions and other toxicities. Conclusions Single-dose liposomal amphotericin B is a better alternative to daily amphotericin B. In addition to less toxicity, nosocomial infections, reduced hospital stay, and the potential for lower hospitalisation costs, the nursing implications should not be discounted. Quality nursing care is a finite resource in low- and middle-income countries, and single-dose amphotericin B reduced the nursing time required for the care of patients with cryptococcal meningitis.<\/ns3:p>","DOI":"10.12688\/wellcomeopenres.21450.2","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:09:52Z","timestamp":1729163392000},"page":"253","update-policy":"https:\/\/doi.org\/10.12688\/wellcomeopenres.crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Using single-dose liposomal amphotericin B for cryptococcal meningitis induction therapy: nurse pearls and practical perspectives"],"prefix":"10.12688","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3955-8107","authenticated-orcid":false,"given":"Jane Frances","family":"Ndyetukira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5270-3539","authenticated-orcid":false,"given":"Richard","family":"Kwizera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Ahimbisibwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-5064","authenticated-orcid":false,"given":"Carol","family":"Namujju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4138-240X","authenticated-orcid":false,"given":"David B.","family":"Meya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"873-81","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global Burden of Disease of HIV-associated cryptococcal meningitis: an updated analysis.","volume":"17","author":"R Rajasingham","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"e101-8","DOI":"10.1097\/QAI.0b013e31828e1e56","article-title":"Cost-effective diagnostic checklists for meningitis in resource-limited settings.","volume":"63","author":"K Durski","year":"2013","journal-title":"J Acquir Immune Defic Syndr."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"1748-55","DOI":"10.1016\/S1473-3099(22)00499-6","article-title":"The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis.","volume":"22","author":"R Rajasingham","year":"2022","journal-title":"Lancet Infect Dis."},{"key":"ref-4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2023.101438","article-title":"Fungal diseases in Africa: closing the gaps in diagnosis and treatment through implementation research and advocacy.","volume":"33","author":"F Bongomin","year":"2023","journal-title":"J Mycol Med."},{"key":"ref-5","doi-asserted-by":"publisher","DOI":"10.3390\/jof8121236","article-title":"Invasive fungal diseases in Africa: a critical literature review.","volume":"8","author":"F Bongomin","year":"2022","journal-title":"J Fungi (Basel)."},{"key":"ref-6","doi-asserted-by":"publisher","DOI":"10.1177\/20499361241228345","article-title":"Re-estimation of the burden of serious fungal diseases in Uganda.","volume":"11","author":"F Bongomin","year":"2024","journal-title":"Ther Adv Infect Dis."},{"key":"ref-7","article-title":"Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV","year":"2022"},{"key":"ref-8","article-title":"Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children","year":"2018"},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"90-9","DOI":"10.1007\/s40475-015-0046-y","article-title":"Cryptococcal meningitis: diagnosis and management update.","volume":"2","author":"M Abassi","year":"2015","journal-title":"Curr Trop Med Rep."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"649-660","DOI":"10.1177\/1744987118824625","article-title":"The conundrum of clinical trials and standard of care in sub-Saharan Africa - the research nurse perspective.","volume":"24","author":"J Ndyetukira","year":"2019","journal-title":"J Res Nurs."},{"key":"ref-11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0284165","article-title":"Adherence of health workers to guidelines for screening and management of cryptococcal meningitis in Uganda.","volume":"18","author":"O Namuju","year":"2023","journal-title":"PLoS One."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"2487-98","DOI":"10.1056\/NEJMoa1312884","article-title":"Timing of Antiretroviral Therapy after diagnosis of cryptococcal meningitis.","volume":"370","author":"D Boulware","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"843-51","DOI":"10.1016\/S1473-3099(19)30127-6","article-title":"Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.","volume":"19","author":"J Rhein","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"809-18","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.","volume":"16","author":"J Rhein","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"35-43","DOI":"10.1016\/s0163-4453(94)95956-0","article-title":"Liposomal amphotericin B, AmBisome.","volume":"28 Suppl 1","author":"R Hay","year":"1994","journal-title":"J Infect."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"225-32","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.","volume":"51","author":"R Hamill","year":"2010","journal-title":"Clin Infect Dis."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"1109-20","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-dose liposomal amphotericin B treatment for cryptococcal meningitis.","volume":"386","author":"J Jarvis","year":"2022","journal-title":"N Engl J Med."},{"key":"ref-18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010825","article-title":"The acceptability of the AMBITION-cm treatment regimen for HIV-associated cryptococcal meningitis: findings from a qualitative methods study of participants and researchers in Botswana and Uganda.","volume":"16","author":"D Lawrence","year":"2022","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-19","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4209-7","article-title":"Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study.","volume":"19","author":"C Ahimbisibwe","year":"2019","journal-title":"BMC Infect Dis."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"722-4","DOI":"10.3201\/eid2004.131277","article-title":"Nosocomial drug-resistant bacteremia in 2 cohorts with cryptococcal meningitis, Africa.","volume":"20","author":"R Rajasingham","year":"2014","journal-title":"Emerg Infect Dis."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"e1845-e1854","DOI":"10.1016\/S2214-109X(22)00450-8","article-title":"Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial.","volume":"10","author":"D Lawrence","year":"2022","journal-title":"Lancet Glob Health."},{"key":"ref-22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu070","article-title":"Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings.","volume":"1","author":"N Bahr","year":"2014","journal-title":"Open Forum Infect Dis."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"13-20","DOI":"10.1111\/hiv.12387","article-title":"Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis.","volume":"18","author":"L Tugume","year":"2017","journal-title":"HIV Med."},{"key":"ref-24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx127","article-title":"Acute Kidney Injury and urinary biomarkers in Human Immunodeficiency Virus-associated cryptococcal meningitis.","volume":"4","author":"C Schutz","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"944-949","DOI":"10.1093\/cid\/ciac792","article-title":"How applicable is the single-dose AMBITION regimen for Human Immunodeficiency Virus\u2013associated cryptococcal meningitis to high-income settings?","volume":"76","author":"T Harrison","year":"2023","journal-title":"Clin Infect Dis."},{"key":"ref-26","article-title":"Gilead sciences announces steep discounts for ambisome to treat cryptococcal meningitis in low- and middle-income countries","year":"2018"},{"key":"ref-27","article-title":"Unitaid supports new global initiative to end cryptococcal meningitis deaths by 2030","year":"2021"},{"key":"ref-28","article-title":"WHO model list of essential medicines","year":"2019"}],"container-title":["Wellcome Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-253\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-253\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-253\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:09:58Z","timestamp":1729163398000},"score":1,"resource":{"primary":{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-253\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":28,"URL":"https:\/\/doi.org\/10.12688\/wellcomeopenres.21450.2","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/wellcomeopenres.21450.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.21956\/wellcomeopenres.25658.r109081","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/wellcomeopenres.25658.r109083","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/wellcomeopenres.25658.r115649","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/wellcomeopenres.25658.r109076","asserted-by":"object"}]},"ISSN":["2398-502X"],"issn-type":[{"value":"2398-502X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"Indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-253\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.21956\/wellcomeopenres.23718.r91181, Olivier Paccoud, Department of Infectious Diseases and Tropical Medicine, University Paris Cit\u00e9, Paris, \u00cele-de-France, 12 Aug 2024, version 1, indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-253\/v1#referee-response-91181","order":0,"name":"referee-response-91181","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/wellcomeopenres.23718.r102529, Carolina Firacative, Studies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, Universidad del Rosario, Bogota, 08 Oct 2024, version 1, indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-253\/v1#referee-response-102529","order":1,"name":"referee-response-102529","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by Wellcome [098316, 214321 and 203135]. AMBITION-CM study was also jointly supported by a grant (TRIA2015-1092) through the European and Developing Countries Clinical Trials Partnership, with assistance from the Swedish International Development Cooperation Agency, as well as by funding from the U.K. Department of Health and Social Care, the U.K. Foreign Commonwealth and Development Office, the U.K. Medical Research Council, and Wellcome Trust, through the Joint Global Health Trials scheme (MR\/P006922\/1). Funding was also provided by the National Institute for Health Research (NIHR) through a Global Health Research Professorship (RP-2017-08-ST2-012, to Dr. Jarvis) with aid from the U.K. government to support global health research. Dr. Meintjes was supported by grants (098316, 214321, and 203135) from Wellcome and a grant (64787) from the South African Research Chairs Initiative of the Department of Science and Technology and the National Research Foundation of South Africa. Diagnostic testing in Uganda was supported by a grant (R01NS086312) from the National Institute of Neurological Disorders and Stroke. Liposomal amphotericin B (AmBisome) was donated by Gilead Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}